SBFMSBFMHealthcare · Drug Manufacturers - Specialty & Generic

SBFM Stock Forecast: Sunshine Biopharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.25
−4.26% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 34 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$1.9M
Ticker Nerd rank
34/ 100
Median analyst target
$1,120
Analysts covering
—
Revenue$9.3M−1.6% y/y
Operating income−$1.6M
Net income−$1.6M
Free cash flow−$923K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.7%
1M
−48.9%
YTD
−99.1%
1Y
−99.2%
From 52W high
−99.2%
From 52W low
0.0%
$2
$296
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Sunshine Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
34/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
64
Accruals
58
Revisions
57
Volatility
34
Growth
31
Issuance
27
Momentum
17
Value
7

Quality (64): The business earns solid, repeatable profits on what it owns.

Value (7): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SBFM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SBFM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$200$400$600$800$1,000$1,200Jan 26Apr 26Jul 26Oct 26SBFMHigh $1,120Median $1,120Low $1,120

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 Oct 2025Aegis CapitalReiteratesBuy$7.00
5 Dec 2024Aegis CapitalReiteratesBuy—
7 Aug 2023Aegis CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SBFM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SBFM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Sunshine Biopharma, Inc. returned −99.2% against +6.9% for the S&P 500, dividends included.

SBFM vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26SBFMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SBFM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.1×

Cheaper than 96% of US stocks

Price / book
0.0×

Cheaper than 98% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
0.3%

Higher than 29% of US stocks

Earnings growth (YoY)
—
Gross margin
26.2%

Higher than 29% of US stocks

Operating margin
−16.8%

Higher than 24% of US stocks

Net margin
−17.5%

Higher than 17% of US stocks

Returns & dividend
Return on equity
−23.4%

Higher than 31% of US stocks

Return on assets
−11.4%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sunshine Biopharma, Inc. has a market value of $1.9M.

  • Revenue in the twelve months to 30 June 2026: $35.3M. The latest quarter shrank 1.6% year on year.

  • Net income over the same four quarters: −$5.8M, a −16.5% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$5.5M.

  • Shares outstanding: 2.4M.

  • forward P/E: 0.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Sunshine Biopharma, Inc. employs 50 people — $707K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

SBFM and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
SBFMSunshine Biopharma, Inc.$1.9M34
SXTCChina Sxt Pharmaceuticals, Inc.$1.8M7
PRFXPRF Technologies Ltd.$1.7M4
GELSGelteq Ltd.$2.9M10
APUSApimeds Pharmaceuticals US, Inc.$3.0M11
SNOASonoma Pharmaceuticals, Inc.$3.7M21
IMCCIM Cannabis Corp.$921,900.0024

Take a look at SBFM’s peer groups, ranked by the model: healthcare stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Sunshine Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about SBFM

How does Ticker Nerd's model rank SBFM?

As at 21 Nov 2026, Sunshine Biopharma, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (64 of 100).

What is the SBFM stock forecast for 2030?

No analyst covering Sunshine Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SBFM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1,120 to $1,120 over the next 12 months.

How has SBFM stock performed over the past year?

Sunshine Biopharma, Inc. returned -99.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sunshine Biopharma, Inc. do?

Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing medicines for oncology, antiviral, and other prescription drug markets. The company’s current business spans prescription generic pharmaceuticals and nonprescription over-the-counter products through its operating subsidiaries, alongside a proprietary drug-development pipeline targeting areas with significant unmet medical need.

Company

About Sunshine Biopharma, Inc.

Sunshine Biopharma Inc. is a pharmaceutical company focused on developing and commercializing medicines for oncology, antiviral, and other prescription drug markets. The company’s current business spans prescription generic pharmaceuticals and nonprescription over-the-counter products through its operating subsidiaries, alongside a proprietary drug-development pipeline targeting areas with significant unmet medical need. Its portfolio includes generic prescription medicines available in Canada, science-based nutritional supplements, and research programs centered on small-molecule, mRNA, and protease-inhibitor candidates. Sunshine Biopharma Inc. serves as a diversified life-sciences platform that combines marketed healthcare products with ongoing therapeutic development, giving it a role in both established pharmaceutical distribution and early-stage drug innovation. Headquartered in Fort Lauderdale, Florida, the company operates primarily in the United States and Canada.

CEO Dr. Steve N. Slilaty Ph.D. · 50 employees · United States · https://sunshinebiopharma.com